MapLight Therapeutics (MPLT) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on CNS disorders, leveraging a proprietary platform to identify and modulate disease-relevant neural circuits.

• Lead candidate ML-007C-MA targets schizophrenia and Alzheimer's disease psychosis (ADP) via M₁/M4 muscarinic agonism, with a precision-matched peripheral antagonist to improve tolerability.

• Pipeline includes ML-004 for autism spectrum disorder (ASD), ML-021 for Parkinson’s disease, and ML-009 for hyperactivity/impulsivity disorders, with all programs retaining global rights.

• Management team and founders have deep neuroscience and drug development expertise, supported by leading investors and scientific advisors.

Financial performance and metrics

• Net losses: $77.6M (2024), $55.7M (2023), $52.2M (H1 2025); accumulated deficit of $251.6M as of June 30, 2025.

• Operating expenses: $82.9M (2024), $57.2M (2023), $54.2M (H1 2025), driven by R&D and increased headcount.

• Cash, cash equivalents, and short-term investments: $60.5M as of June 30, 2025; $200M raised in Series D preferred stock in July/Sept 2025.

• Pro forma net tangible book value post-offering: $12.01/share; immediate dilution to new investors: $4.99/share.

Use of proceeds and capital allocation

• Net proceeds from IPO and concurrent private placement estimated at $234.8M.

• Planned allocation: $100–120M for ML-007C-MA in schizophrenia (Phase 2), $50–70M for ML-007C-MA in ADP (Phase 2), $15–25M for ML-004 in ASD (Phase 2), $30–40M for preclinical R&D, remainder for working capital and general purposes.

• Proceeds expected to fund operations through 2027; additional capital will be needed for regulatory approval and commercialization.